The leadership team at Corium brings together industry-leading experts in drug development, manufacturing, and commercialization who are dedicated to doing more for our partners and patients.
Perry Sternberg, CEO of Corium Inc, delivers a vision of a healthcare company that is patients' and caregivers' partner of choice. Based on an ethos of community and compassion, Corium strives to make a difference in the lives of others. As CEO, Perry focuses the company's efforts on the empowerment of patients, caregivers, and its employees.
According to Perry, every existing and potential relationship relies on the organic building of good communication and trust, not one-sided messaging. Leading a healthcare business means being approachable, treating others with respect, and being open and eager to hear others' ideas. As Perry says, “Every person has something valuable and important to bring to the table when it comes to improving patient and caregiver outcomes.”
In his 25 years of experience in biotechnology and pharmaceuticals, Perry has overseen the launches of more than 20 products across a wide range of therapeutic areas in diverse markets. Under his leadership, Corium has filed and submitted for FDA approval a prescription treatment for Alzheimer's disease. The company has also continued its strategic partnerships to bring to market an ADHD treatment and produce contraception and in-demand oral care products. Perry is passionate about, and thrilled by, the future that Corium is building for the people the company seeks to serve.
Perry spends his downtime with his wife, 3 children, and their family dog, and enjoys travel.
Mr. Arsulowicz is the Vice President, Operations for Corium's Grand Rapids, Michigan, site. Dan has more than 15 years of experience and management in engineering and R&D development and operations in the pharmaceutical, medical device, and OTC fields. He has led his teams through successful regulatory filings and approvals, as well as commercial scale-up of multiple transdermal, medical device, and oral healthcare products. Prior to joining Corium in April 2002, Dan held R&D and operations roles at Amway Corporation, where he was responsible for process development, scale-up, continuous improvement programs, and general operational support for various products. Dan received a B.S. in Chemical Engineering from the University of Michigan and an M.B.A. from Grand Valley State University.
Mr. Gersten is an accomplished General Counsel and brings more than 30 years of experience providing strategic advice to Executive Management, Boards of Directors, and companies across a broad range of complex business and legal issues facing biotechnology and pharmaceutical companies. Prior to joining Corium, Mr. Gersten served as Senior Vice President, General Counsel, Chief Ethics and Compliance Officer, and Secretary for Dynavax Technologies. Prior to his role at Dynavax Technologies, he served as Global Vice President of Ethics and Compliance at AbbVie, where he helped build the compliance program and organization. Mr. Gersten also previously worked at Abbott, where he served as Global Vice President and General Counsel to several business units, setting global legal strategies and functional plans, as well as overseeing the internal legal organization and external counsel, and Global Vice President and Chief Regulatory and Compliance Counsel. Mr. Gersten held various positions of increasing responsibility with the US Department of Justice, law firms in New York and Washington, DC, and the US Attorney's Office. Mr. Gersten holds a JD from the Boston University School of Law and a BS, with a concentration in finance, from the Boston University Questrom School of Business.
Ms. Lynch has more than 13 years of experience in the biotechnology, pharmaceutical and medical device industries and spent the last 6+ years focused on supporting executive leadership, corporate strategy, organizational and governance design, and assessment of business development opportunities. Prior to joining Corium, Ms. Lynch served as the Chief of Staff for the U.S. Commercial Business and Neuroscience Division at Shire Plc, where she provided strategic guidance and consultative expertise for Shire's $10B U.S. business. During her time at Shire, Ms. Lynch also supported the U.S. integration efforts for Shire's acquisition by Takeda Pharmaceutical Company. Before joining Shire, Ms. Lynch was an Engagement Manager at IQVIA within their Management Consulting practice and focused on Strategy and Portfolio Analysis. Prior to that she held various roles of increasing responsibility at multiple divisions of Johnson & Johnson supporting new product development, product launch, and manufacturing improvements for medical devices, diagnostics, biologics, and combination therapies. She received an M.B.A from New York University's Stern School of Business and a B.S. degree in biochemistry from Lehigh University.
Mr. Miller brings nearly 30 years of finance experience, including working in the biopharmaceutical industry supporting commercial activities and US and international launches. Prior to joining Corium, Mr. Miller served as the Head of Finance for Global Commercial and Corporate Financial Planning and Analysis (FP&A) at Shire Plc. During his 15 years at Shire, he had responsibility for internal audit, finance operations and shared services, business partnering/FP&A, and served as interim CFO for the first quarter of 2018. He started his career at KPMG, and, during his 8 years at the firm, had roles of increasing responsibility in the assurance practice. Mr. Miller holds a bachelor's degree in Accounting from LaSalle University and a master's degree in Finance from Drexel University.
Mr. Neeley has more than 30 years of experience in the biotechnology and pharmaceutical industries, with commercial and government markets experience across a wide range of therapeutic areas in global markets. Prior to joining Corium, Mr. Neeley was with Shire Plc, where he served in various roles, most recently as the Head of Market Access and U.S. Pricing and before that as Head of Global Market Access. During his 17+ years at Shire, he had responsibility for market access, US government pricing and reporting, managed markets, government payor channel, and distribution. He has extensive product launch experience and has spearheaded several large-scale market access strategic initiatives that resulted in increased efficiency and multimillion-dollar cost savings. Before joining Shire, Mr. Neeley was a managing partner and co-founder at Viking Healthcare Solutions, Inc. Prior to that, he spent time at Astra Pharmaceuticals and Boots Pharmaceuticals in various roles of increasing responsibility in managed markets, marketing, and sales. Mr. Neeley holds a bachelor's degree in Business from Palm Beach Atlantic University and a Master of Business Administration from Florida Atlantic University.
Dr. Ocheltree has more than 30 years of diverse pharmacy, pharma and biopharma experience, including 8 years at the US FDA in the Office of New Drug Quality Assessment as a reviewer and division director. His depth of knowledge spans regulatory affairs, product development, manufacturing, project management and pharmacy practice and he has expertise across platforms ranging from small molecules, biologics, and botanicals, to combination products and generic drugs.
Dr. Ocheltree was most recently at Certara as Vice President of Regulatory Strategy and CMC, expanding their drug development and regulatory capabilities. Previously, he founded PharmTree Consultants, an independent regulatory consulting firm specializing in chemistry, manufacturing and controls (CMC) regulatory affairs. Prior to PharmTree, he served as Senior Director of Regulatory CMC and Senior Director of Regulatory Policy and Intelligence at AbbVie. While at the FDA, Dr. Ocheltree reviewed and responded to INDs, NDAs, and sNDAs, participated in industry meetings, led multi-functional teams, developed guidances (including transdermal and botanical) and championed the use of Quality by Design (QbD), Process Analytical Technology (PAT), Real Time Release Testing (RTRT) and Product Lifecycle Management. Before his tenure at the FDA, Dr. Ocheltree held various scientific and technical roles at 3M Pharmaceuticals, Cardinal Health and Morton Grove Pharmaceuticals, and worked in both retail and hospital pharmacy, establishing a first-in-class specialty service pharmacy for Greenville Health Corporation. He is also an adjunct professor at the University of Wisconsin and has served in the same role and as pharmacy preceptor for multiple other colleges and universities. He is an active member of numerous trade and professional organizations and has served on PhRMA, EFPIA and IFPMA committees. Dr. Ocheltree holds a BA in Interdisciplinary Studies and a BS in Pharmacy from the University of South Carolina and a Ph.D. in Pharmaceutics from the Medical University of South Carolina.
Dr. Charles Oh has more than 15 years of experience in clinical development, medical affairs, and business development in the biotech, pharmaceutical and medical device fields. He has led teams through multiple drug and device development programs resulting in the successful regulatory filings and approvals of products in North America and Europe. He most recently served as the Senior Vice President, Clinical Development at Acorda Therapeutics. Prior to that, Dr. Oh held roles of increasing responsibility and leadership at Purdue Pharma and Johnson & Johnson.
Dr. Oh received his medical degree from the Washington University in St. Louis. He also has an MBA from the University of North Carolina at Chapel Hill and a BS in Biology from the University of Miami (FL).
As the Head of the CNS Business Unit, Mr. Price is responsible for sales, marketing, and commercial operations at Corium. He brings nearly 30 years of experience in biotech, pharmaceutical, and healthcare marketing with broad expertise in brand strategy, marketing, sales, life cycle management, market research, and commercial operations. Mr. Price most recently served as the Executive Vice President, Client Services at RevHealth, a full-service healthcare marketing agency that specializes in pharmaceutical and healthcare strategy, marketing, advertising, and education. Prior to that, he was the General Manager of Portugal at Abbott Laboratories, with responsibility for several therapeutic areas and the growth of numerous brands, including Humira® and Kaletra®. Earlier in his career, Mr. Price held roles of increasing responsibility and leadership in the U.S. at Abbott Laboratories and GlaxoSmithKline plc. He holds a bachelor's degree in Economics and Psychology from the University of Michigan and a master's degree in Management from Northwestern University.
Ms. Spaeth has more than 14 years of experience in the biotechnology and pharmaceutical industries, with broad HR expertise including organizational design, change management, talent development, employee engagement, and leadership coaching. Prior to joining Corium, Ms. Spaeth served as the Head of HR for R&D, Technical Operations and Corporate Functions at Sage Therapeutics, where she was responsible for evolving the organizational structure and implementing the processes to transition from a Clinical R&D organization to a commercial product company. Before joining Sage, Ms. Spaeth served as the Head of HR for US Commercial at Shire Plc. Prior to that, she held various roles of increasing responsibility at Shire Plc, including HR business partner, compensation manager, and change management consultant. In 2018, Ms. Spaeth was recognized by the Healthcare Business Women's Association as a Rising Star. She holds a bachelor's degree in Hospitality and Tourism Management from the University of Massachusetts, Amherst, and a master's degree in Human Resources from Suffolk University.